The clinical trial reported subjects with severe postpartum depression saw statistically significant improvements that continued at days 15, 28, and 45 when researchers assessed symptoms using the Hamilton Depression Rating Scale.
All clinical trials conducted with zuranolone studied a 14-day treatment course, Deligiannidis said, noting the drug is intended for use as an acute treatment course for PPD, not long-term use.
When asked how zuranolone measures up to the other FDA-approved drug, the injectable Zurlresso, Deligiannidis said there are currently “no head-to-head clinical studies” with the two drugs, so their comparative effectiveness is unknown.
“Both Zulresso and zuranolone are associated with a rapid reduction of PPD symptoms,” Deligiannidis said.